Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
27.10
+0.70 (2.65%)
At close: Apr 9, 2026, 4:00 PM EDT
26.85
-0.25 (-0.92%)
Pre-market: Apr 10, 2026, 7:19 AM EDT
Eton Pharmaceuticals Revenue
In the year 2025, Eton Pharmaceuticals had annual revenue of $79.95M with 104.94% growth. Eton Pharmaceuticals had revenue of $21.28M in the quarter ending December 31, 2025, with 82.72% growth.
Revenue (ttm)
$79.95M
Revenue Growth
+104.94%
P/S Ratio
9.25
Revenue / Employee
$1,817,045
Employees
44
Market Cap
739.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.95M | 40.94M | 104.94% |
| Dec 31, 2024 | 39.01M | 7.37M | 23.29% |
| Dec 31, 2023 | 31.64M | 10.39M | 48.90% |
| Dec 31, 2022 | 21.25M | -581.00K | -2.66% |
| Dec 31, 2021 | 21.83M | 21.79M | 55,879.49% |
| Dec 31, 2020 | 39.00K | -920.00K | -95.93% |
| Dec 31, 2019 | 959.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Tilray Brands | 858.28M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Esperion Therapeutics | 403.14M |
| Ironwood Pharmaceuticals | 296.15M |
| Kamada | 180.46M |
ETON News
- 21 days ago - Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 5 weeks ago - Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - GlobeNewsWire
- 6 weeks ago - US FDA approves Eton Pharma's hormonal disorder drug - Reuters
- 6 weeks ago - Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution - GlobeNewsWire
- 7 weeks ago - Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - GlobeNewsWire
- 2 months ago - Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - GlobeNewsWire
- 4 months ago - Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th - GlobeNewsWire